Discrimination between circulating endothelial cells and Blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in Cancer therapy

Neoplasia

Volumn 13, Issue 10, 2011, Pages 980-990

  Starlinger, Patrick ^a   Brugger, Philipp ^a   Reiter, Christian ^a   Schauer, Dominic ^a   Sommerfeldt, Silvia ^a   Tamandl, Dietmar ^a   Kuehrer, Irene ^a   Schoppmann, Sebastian F ^a   Gnant, Michael ^a   Brostjan, Christine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINODACTINOMYCIN; BEVACIZUMAB; CD146 ANTIGEN; CD3 ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; FIBRINOGEN RECEPTOR; GEMCITABINE;

ADULT; AGED; ARTICLE; BLOOD CELL; BLOOD SAMPLING; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CELL POPULATION; CIRCULATING ENDOTHELIUM CELL; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE ACTIVATION; THROMBOCYTE; TREATMENT OUTCOME;

EID: 80054795920     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11916     Document Type: Article

References (34)

1. Gasparini G, Longo R, Fanelli M, and Teicher BA (2005). Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23, 1295-1311.
2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, and Johnson DH (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355, 2542-2550.
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-2342.
4. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, and Davidson NE (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357, 2666-2676.
5. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, et al. (2010). Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28, 3617-3622.
6. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, et al. (2009). Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27, 2231-2237.
7. Bertolini F, Mancuso P, Shaked Y, and Kerbel RS (2007). Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today 12, 806-812.
8. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, and Sorensen AG (2009). Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6, 327-338.
9. Mancuso P and Bertolini F (2010). Circulating endothelial cells as biomarkers in clinical oncology. Microvasc Res 79, 224-228.
10. Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, Pivot X, Veyret C, Bergougnoux L, de Cremoux P, Milano G, et al. (2010). Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 21, 1765-1771.
11. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, et al. (2006). Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108, 452-459.
12. Strijbos MH, Gratama JW, Schmitz PI, Rao C, Onstenk W, Doyle GV, Miller MC, de Wit R, Terstappen LW, and Sleijfer S (2010). Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. Eur J Cancer 46, 2027-2035.
13. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, et al. (2009). Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27, 3020-3026.
14. Khan SS, Solomon MA, and McCoy JP Jr (2005). Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 64, 1-8.
15. Strijbos MH, Kraan J, den Bakker MA, Lambrecht BN, Sleijfer S, and Gratama JW (2007). Cells meeting our immunophenotypic criteria of endothelial cells are large platelets. Cytometry B Clin Cytom 72, 86-93.
16. Dignat-George F, Sabatier F, Blann A, and Woywodt A (2007). Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay? J Clin Oncol 25, e1-e2.
17. Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, Willett CG, and Jain RK (2006). Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 24, 1449-1453.
18. Goon PK, Watson T, Stonelake PS, and Lip GY (2007). The quest for circulating endothelial cell standardization: the peril of platelets. Cytometry B Clin Cytom 72, 416.
19. Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, Braidotti P, Wu HK, Zurita AJ, Saronni L, et al. (2009). Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 15, 267-273.
20. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, and Bertolini F (2001). Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97, 3658-3661.
21. Brostjan C, Bayer A, Zommer A, Gornikiewicz A, Roka S, Benko T, Yaghubian R, Jakesz R, Steger G, Gnant M, et al. (2003). Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. Cancer 98, 2291-2301.
22. Brostjan C, Gebhardt K, Gruenberger B, Steinrueck V, Zommer H, Freudenthaler H, Roka S, and Gruenberger T (2008). Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels. Clin Cancer Res 14, 2065-2074.
23. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, et al. (2005). Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23, 8136-8139.
24. Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Tokutomi T, and Sekine I (2003). Circulating endothelial cells in Kawasaki disease. Clin Exp Immunol 131, 536-540.
25. Elshal MF, Khan SS, Takahashi Y, Solomon MA, and McCoy JP Jr (2005). CD146 (Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of lymphocyte subset activation in normal peripheral blood. Blood 106, 2923-2924.
26. Matejuk A and Afentoulis M (2006). Association of CD45(dim)VLA-4 (+) cells with the NKT cell lineage and their selective expression of IL-13, IP-15, and CCR3 transcripts. Arch Immunol Ther Exp (Warsz) 54, 183-191.
27. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, Tagliafico E, Ferrari S, Robey PG, Riminucci M, et al. (2007). Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131, 324-336.
28. Sabbaghian MS, Rothberger G, Alongi AP, Gagner JP, Goldberg JD, Rolnitzky L, Chiriboga L, Hajdu CH, Zagzag D, Basch R, et al. (2010). Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma. Anticancer Res 30, 2911-2917.
29. Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, Dellapasqua S, Campagnoli E, Shaked Y, Goldhirsch A, et al. (2009). Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 15, 7652-7657.
30. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, et al. (2008). Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26, 4899-4905.
31. Goon PK, Lip GY, Stonelake PS, and Blann AD (2009). Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index. Neoplasia 11, 771-779.
32. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, and Tempero MA (2010). A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 66, 1051-1057.
33. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, et al. (2007). Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinibresistant gastrointestinal stromal tumor. Clin Cancer Res 13, 2643-2650.
34. Starlinger P, Brugger P, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann SF, Gnant M, and Brostjan C (2011). Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment. Neoplasia 13, 419-427.